- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Kunnath Pharma unveils immunity booster capsules under brand name Viromune in India

New Delhi: Herbal products maker Kunnath Pharmaceuticals on Thursday said it has launched antiviral immunity booster capsules under the brand name 'Viromune' across the country and is looking to achieve a turnover of Rs 2,000 crore in the next three years.
Viromune is an Ayurvedic formulation consisting of 17 potent herbs and their properties range from antiviral to natural immunity boosting, along with a well balanced blend of essential vitamins and minerals, Kunnath Pharmaceuticals said.
The aim is to sell 25 lakh packets of the product in the first year, 50 lakh packets in the second year and 1 crore in the third year across the country, Kunnath Pharmaceuticals MD K C Abraham told.
"We are planning to achieve the Rs 2,000 crore turnover target in the coming three years. Our new product line will help us in this process," he added.
The company is spending over Rs 100 crore in research and development and on the new products, Kunnath Pharmaceuticals in a statement.
"We are already exporting our products to 12 countries, which include Australia, Canada, the UAE etc. (The) company is envisaging a plan to reach at least 75 countries in the near future," Abraham said.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story